Multiple myeloma (MM) is a clonal B-cell neoplasm that accounts for 10% of all malignant hematologic neoplasms and that affects terminally differentiated B cells (i.e., plasma cells). It is now well recognized that the cytokine interleukin-6 (IL-6) is a major cytokine that promotes the proliferation of malignant plasma cells in MM. The IL-6 gene can be regulated by the NOTCH genes products. We have previously shown that the NOTCH ligand, JAG2, is overexpressed in MM. To investigate the mechanism(s) leading to JAG2 overexpression in MM, we assessed potential epigenetic modifications of the JAG2 promoter. We showed that the JAG2 promoter region is aberrantly acetylated in MM cell lines and patient samples. The acetylation state of histones is regulated by the recruitment of histone deacetylases (HDAC). HDACs are typically recruited to promoter regions through interaction with nuclear corepressors such as SMRT. SMRT levels were therefore investigated. Interestingly, MM cell lines and patient samples presented significantly reduced SMRT levels. The experiments suggest a correlation between constitutive acetylation of the JAG2 core promoter in the MM cell lines and reduced levels of the SMRT corepressor that recruits HDAC to promoter regions. Finally, SMRT function restoration induced JAG2 down-regulation as well as MM cell apoptosis.
Introduction
Multiple myeloma (MM), a clonal B-cell malignancy, characterized by accumulation of malignant plasma cells in the bone marrow, is the second most common hematologic malignancy in the United States (1, 2) . Although the exact mechanism governing the ability of myeloma cells to develop resistance remains unknown, interaction of tumor cells with the microenvironment with deregulation of the apoptotic mechanisms has been reported. In the bone marrow microenvironment, MM cells interact with the cytokine-secreting stromal cells through intracellular adhesion molecules, resulting in activation of stromal cells (including osteoclasts) and production of prosurvival cytokines, which further supports the growth and survival of myeloma cells (3) .
It is now well established that the cytokine interleukin-6 (IL-6), produced either in an autocrine (by the myeloma cell) or paracrine manner (by the stromal cells), plays an essential role in promoting the proliferation of malignant plasma cells in MM (4) . In addition, elevated IL-6 levels directly correlate with tumor burden, bone destruction, and other tumor-associated activities (5) . MM cells regulate IL-6 production within the microenvironment through induction of stromal cells largely in a cell contact-dependent manner (6) .
The regulation of the IL-6 gene can be affected by a variety of factors, including cytokines, IL-1, tumor necrosis factor a, and, as recently shown, by the products of the NOTCH genes. The NOTCH genes were originally identified in Drosophila melanogaster and are members of an evolutionarily conserved family of transmembrane receptors that help to determine cell fate during development and also function in maintenance of the proliferative capacity of immature cells (7) . The fully processed NOTCH receptors consist of an extracellular subunit (N EC ) that is noncovalently bound to a transmembrane subunit (N TM ), which includes the cytoplasmic domain (N IC ). The NH 2 -terminal sequence of N IC contains the highaffinity interaction site for the transcription factor CBF1/RBP-Jj (8) , which can regulate the transcription of numerous genes including IL-6 (9, 10). This CBF1-mediated induction of IL-6 is a potential mechanism by which activation of NOTCH, through ligand binding, may promote plasma cell survival and proliferation in the bone marrow of MM patients. In the mammalian system, five NOTCH ligands are currently known, named Delta-like 1, Delta-like 3, Delta-like 4, JAG1, and JAG2 (11) . Recently, our group and others (12) (13) (14) reported that MM cells can induce the production of IL-6 in stromal cells through overexpression of JAG2 and activation of the NOTCH receptors in the stromal cells. As a result, IL-6 can enhance proliferation of the myeloma cells in a paracrine fashion. JAG2 has been shown to be overexpressed in all cell lines and patient samples studied, both at the RNA and protein levels (12) . Whereas chromatin modifications have been shown to be one of the key mechanisms for gene regulation (15) , the mechanism underlying JAG2 overexpression in MM remains unknown.
We therefore investigated the potential modifications of the JAG2 core promoter region in different MM cell lines as well as in patient samples. The acetylation state of histones is mainly regulated by the recruitment of histone deacetylases (HDAC; refs. 16, 17) . Studies by several groups have shown that this complex is recruited to nuclear receptors through SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) and a related corepressor, NCOR (18) (19) (20) . The ability of the SMRT containing ''silencing complex'' to deacetylate histones results in a condensed chromatin state that is inhibitory to transcription (21) . The activities of HDACs are also tightly regulated. For example, HDAC3 is primarily inactive but becomes activated when it forms a complex with SMRT (22) .
In this report, we showed reduced SMRT RNA and protein levels in MM cell lines and primary MM cells from patients and, as a consequence, a reduced level of SMRT-activated HDAC3. Furthermore, we report that partial restoration of SMRT activity in MM cells led to a reduction of JAG2 expression, suggesting that JAG2 overexpression is a consequence of reduced histone deacetylation of its core promoter, which seems to be due to a partial loss of the SMRT transcription corepressor.
Materials and Methods

Samples and Cell Lines
RPMI-8226, U266, and OPM2 (MM cell lines) were purchased from American Type Culture Collection; EBV-LIN (lymphoblastoid cell line/ immortalized lymphocytes) was a gift from Dr. Thomas Ellis (The Blood Center of South Eastern Wisconsin, Milwaukee, WI). All cell lines were cultured in RPMI 1640 (Invitrogen) with the addition of 10% fetal bovine serum (FBS) and antibiotics. The MM patient plasma cells (n = 6) were purified using CD138-bound beads (Miltenyi Biotec) with a post-isolation purity of the samples of >95%.
Bisulfite Sequencing
Bisulfite treatment of DNA and subsequent PCR were done as previously described (23) with the exception that the DNA purification before and after alkali desulfonation was done using the Qiagen gel extraction kit (Qiagen). Bisulfite-treated DNA was used as a template in PCR reactions as previously described (23) . The PCR reactions were run for 35 cycles. The primers used to amplify the 276 fragment of the promoter region of JAG2 including the first 43 nucleotides of exon 1 were as follows: forward primer, 5 ¶-GAGGA-GGGGAGGTAGTTTTG-3 ¶; reverse primer, 5 ¶-ACCCRCRCACCTACATATAC-3 ¶. All bisulfite PCR reactions were set up using the buffers and conditions originally defined (23) with the addition of 5% DMSO and an annealing temperature of 56jC. Bisulfite PCR products were cloned using the TOPO-TA cloning kit (Invitrogen). The Qiagen miniprep kit was used to isolate individual clone DNAs. Sequencing of at least five clones per cell line was done by the Sequencing Core Facility at Roswell Park Cancer Institute, Buffalo, NY.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was done using the commercially available Chromatin Immunoprecipitation Assay Kit (Upstate Cell Signaling Solution) according to the manufacturer's recommendations. Briefly, cells (2 Â 10 6 ) were cross-linked by adding formaldehyde (1% final volume) directly to 10 mL culture medium for 10 min at 37jC. Cells were then harvested in SDS lysis buffer with protease inhibitors and incubated on ice for 10 min. Chromatin was sonicated to an average size of 0.2 to 1 kb. After centrifugation, the supernatant was equally divided and diluted 10-fold in chromatin immunoprecipitation dilution buffer containing protease inhibitors. After precleaning with salmon sperm DNA/protein A/agrose-50% slurry for 30 min at 4jC, antibodies were added and the mixture was incubated overnight with gentle rotation at 4jC. Nonspecific IgG has been used as an immunoprecipitation control. Another 60-AL aliquot of salmon sperm DNA/protein A/agrose-50% slurry was then added to the solution and incubated for an additional 4 h at 4jC with gentle rotation. The agarose beads were washed several times with appropriate buffers provided in the kit per manufacturer's recommendations.
The immunoprecipitated protein-DNA complex was eluted and the input and immunoprecipitated chromatin were then incubated at 65jC for 4 h to reverse the formaldehyde cross-links; it was then digested with proteinase K for 4 h at 50jC to remove proteins. The DNA was extracted using the phenol-chloroform method, precipitated with ethanol, and dissolved in water. The antibodies used for chromatin immunoprecipitation were antiacetyl-histone H4 and anti-acetyl-histone H3 (Upstate Cell Signaling Solutions). Immunoprecipitated chromatin was subjected to PCR amplification with JAG2 core promoter specific primers: forward, 5 ¶-TGACCCC-GAGGCCCCGTGCC-3 ¶; reverse, 5 ¶-GCACCGCAGCCAACAAGTTC-3 ¶. The expected size of the PCR product was 270 bp.
Reverse Transcription-PCR
Total RNAs were extracted from cultured cells with an RNA isolation kit (Ambion). The cDNAs were synthesized using a First Strand cDNA Synthesis Kit (MBI Fermentas). The gene-specific primers were SMRT, forward, 5 ¶-TCAGCGGAGTGAAGCAGGAG-3 ¶ and reverse, 5 ¶-TCGATGCTGGCTGAG-GAGAT-3 ¶; JAG2, forward, 5 ¶-AACGGCGCTCGCTGCTATAA-3 ¶ and reverse, 5 ¶-GGTTGCAGTCGTTGGTATTG-3 ¶; and the internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forward, 5 ¶-TTAGCACCCCT-GGCCAAGG-3 ¶ and reverse, 5 ¶-CTTACTCCTTGGAGGCCATG-3 ¶. Because the JAG2 core promoter region as well as JAG2 cDNA present a high GC content, a GC-melt kit (BD Biosciences) was used during the amplification.
The expected amplification products are 494-bp SMRT fragment, 745-bp JAG2 fragment, and 525-bp GAPDH fragment. The PCR products (10 AL) were electrophoresed on a 1% agarose gel impregnated with ethidium bromide and then photographed. The reverse transcription-PCR (RT-PCR) amplifications were repeated thrice to ensure reproducibility of the results.
Real-time PCR
Real-time PCR was done using an ABI PRISM system with SYBR Green detection [SYBR Green ER qPCR kit (Invitrogen)]. Five hundred nanograms of DNA in 2 AL were used as a template. The reactions were carried out in 20 AL final reaction volume containing 0.4 Amol/L of SMRT-specific primers, 2 AL DNA solution, 6.4 AL distilled water, and 10 AL kit-supplied SYBR PCR master mix (including HotStart Ex Taq HS DNA polymerase, reaction buffer, deoxynucleotide triphosphate mix, and SYBR Green I). The thermal profile for the real-time PCR was 95jC for 10 s, followed by 40 cycles of 95jC for 5 s and 60jC for 20 s.
Immunofluorescence
Cytospins were prepared from the cell lines, fixed with acetone for 10 min at room temperature, and air-dried. For immunofluorescence, cells were incubated with a rabbit anti-SMRT polyclonal antibody (ABR) following incubation with the appropriate (mouse or rabbit) FITCconjugated secondary antibody (Santa Cruz Biotechnology). Nuclei were counterstained with 4 ¶,6-diamidino-2-phenylindole (DAPI)-containing antifade solution (Vectashield, Vector Laboratories). Fluorescent images were acquired with an Optiphot microscope (Nikon) through an oil PLAN Apo (100Â, 0.4 app.) and filters specific for FITC and DAPI. The microscope was equipped with a charge-coupled device camera (1300DS, Digital Instruments), and the EasyFISH software (Applied Spectral Imaging, Inc.) was used for capture and background reduction, without additional modifications. Ten different spots were scanned for each slide.
Immunoprecipitation
Nuclear extracts were prepared using the NE-PER Kit (Pierce Biotechnology). The lysates were immunoprecipitated with the polyclonal anti-SMRT antibody (ABR) overnight at 4jC. The immunocomplexes were collected by washing four times with lysis buffer boiled in 1Â Laemmli sample buffer (Bio-Rad) for 10 min and subjected to Western blot analysis with anti-HDAC3 antibody (Upstate Cell Signaling Solution).
Western Blot Analysis
Protein lysates were obtained by incubation of the cells with a lysis buffer [50 mmol/L Tris-HCl (pH 7.4); 1% NP40; 0.25% sodium deoxycholate; 150 mmol/L NaCl; 1 mmol/L EDTA; 1 mmol/L phenylmethylsulfonyl fluoride; 1 mg/mL aprotinin, leupeptin, pepstatin; 1 mmol/L Na 3 VO 4 ; 1 mmol/L NaF]. Cell debris were removed by centrifugation (14,000 Â g, 15 min at 4jC). Proteins (50 Ag) were resolved in 3% to 7% NuPAGE Trisacetate gel (Invitrogen) and transferred onto polyvinylidene difluoride membrane (Amersham) by using a Bio-Rad transfer system (Bio-Rad). The membranes were probed with an anti-HDAC3 (Upstate Cell Signaling Solution), anti-SMRT (Santa Cruz Biotechnology), or anti-JAG2 (Cell Signaling) followed by corresponding secondary antibodies. Western blots were developed using the ECL Plus Western blot detection kit (Amersham).
Generation of a TAT-SMRT Recombinant Protein
The TAT system allows the translocation of folded and often cofactorcontaining proteins across biological membranes. The TAT moiety (ILEQLAQTFK) was amplified by PCR from a pTAT-HA vector (a generous gift from Dr. S. Dowdy, University of California, San Diego, CA) and subcloned into a pET 41a+ vector (Novagen). Next, the TRAC2/SMRT cDNA was digested with EcoRI and XhoI and ligated into this modified TATcontaining pET41. The resulting construct carries both glutathione S-transferase (GST) and His tags in tandem followed by the TRAC2/SMRT cDNA. An engineered thrombin-cleavage site resides between the GST and His tags. The construct was verified by sequencing. The pET41a-SMRT-TAT construct was expressed in Escherichia coli strain BL21 Star (DE3) pLysS (Invitrogen) grown in LB medium supplemented with 50 mg/L kanamycin and 34 mg/L chloramphenicol at 37jC and further induced with 0.5 mmol/L isopropyl-L-thio-B-D-galactopyranoside for 3 h. The GST proteins were purified using a GST-Bind kit (Novagen). Six-microliter aliquots of elution fraction were analyzed by SDS-PAGE.
Effect of TAT-SMRT Protein on the Cells
Uptake of the recombinant proteins by the cells. RPMI-8226 cells were incubated in RPMI 1640 (ÀFBS) containing either TAT-SMRT or TAT scrambled protein (50 ng) for 4 h. After incubation, cells were washed twice with PBS and processed for immunofluorescence as described above. An antibody cocktail containing equal concentrations of rabbit anti-SMRT polyclonal antibody (ABR) and mouse anti-GST monoclonal antibody (mAb; Upstate Cell Signaling Solution) was used for primary incubation followed by incubation with another mixture of antimouse and antirabbit FITCconjugated secondary antibodies (Santa Cruz Biotechnology). Nuclei were counterstained with DAPI.
Effect of recombinant protein uptake on JAG2 expression in MM cells. The same experimental design as described above was used with RPMI-8226 cells. After 4-h incubation, cells were washed twice with PBS and cultured overnight in regular RPMI 1640. RNA was extracted, and RT-PCR was done with the JAG2 -and SMRT-specific primers as described previously.
Annexin V assay. Quantification of apoptotic cells was done using Annexin V staining and flow cytometry. Cells with or without treatment were washed once with PBS before staining with FITC-Annexin V and propidium iodide according to the manufacturer's instructions (Invitrogen). Samples were analyzed with a FACScan (Becton Dickinson) and WinList software (Verity Software House).
Cell viability assays. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) tetrazolium dye reduction assay (R&D Systems) was used to quantify cell viability. All experiments with variable concentrations of the SMRT-TAT recombinant protein using only the RPMI-8226 MM cell line were done. Treatments were set up in quadruplicate with equal number of cells per well using three doses of SMRT-TAT protein (50, 100, and 150 ng of purified protein) incubated for 24 and 48 h. Cell viability was assessed by the MTT assay. The absorbance at 495 nm (A 495 ) of each well was measured using an automated plate reader. The entire experiment was reproduced thrice. The results were analyzed statistically using one-way ANOVA with Bonferroni post-test with statistical significance considered at P < 0.05.
Results
Methylation status of the JAG2 promoter region. Previous studies have shown that MM patients recurrently overexpress JAG2. The JAG2 gene has a 2.6-kb CpG island extending 818 bp upstream from the transcriptional start site and encompassing the core promoter region. This CpG island has a GC content of 76% and an obs/exp CpG ratio of 0.88. We studied the DNA methylation pattern of the JAG2 promoter to assess whether hypomethylation of the CpG island is associated with the regulation of JAG2 expression. Bisulfite sequencing analysis of the promoter region in both expressing and nonexpressing cell lines was done (Fig. 1A) .
Despite various levels of methylation upstream of the core promoter, all samples, regardless of JAG2 expression, showed no methylation in the core promoter region. All samples showed hypermethylation of the two CpG dinucleotides assayed after the transcriptional start site in exon 1. No other methylation pattern was found to correlate with JAG2 expression.
The peripheral blood lymphocyte DNA showed a nearly complete absence of methylation in the entire region assayed. Interestingly, in the JAG2-negative acute lymphoblastic leukemia cell line MUTZ5 and JAG2-positive MM cell line RPMI-8226, both containing a strongly methylated promoted region, the CpG dinucleotide immediately upstream of the core promoter region, the methylation stops at the core promoter. Methylation at the SP1 binding site is absent in all cells except MUTZ5. Overall, these data suggest that changes in DNA methylation at the JAG2 core promoter cannot be responsible for the up-regulation of JAG2 expression observed in MM cell lines. This led us to explore other epigenetic mechanisms in the regulation of JAG2 expression.
Histone acetylation status of JAG2 core promoter region in MM cell lines and patient samples. Because histone acetylation/ deacetylation affects the chromatin structure and can regulate gene transcription, a chromatin immunoprecipitation assay followed by PCR was done on EBV-LIN, a lymphoblastoid cell line (JAG2 negative), and RPMI-8226 (JAG2 positive), a MM cell line, using antibodies specific for acetylated histones H3 and H4.
The experiments showed a differential pattern of histone H4 acetylation between the MM and the control cell lines (Fig. 2A) . The expected 230-bp JAG2 core promoter fragment was detected in RPMI-8226, indicating an acetylated state of the histones conducive to a chromatin structure permissive to transcriptional initiation. The absence of an amplified product for the JAG2-negative cell line indicated a lack of acetylated histones consistent with a silent chromatin. No significant difference in the level of H3 acetylation between the MM and control cell lines was observed. The results were confirmed using two additional MM cell lines (OPM2 and U266; Fig. 2B ).
To validate the acetylation results obtained in the cell lines, similar chromatin immunoprecipitation experiments were done in malignant plasma cells purified from MM patients (n = 6). Due to a limited amount of cells, the H3 acetylation level was not assessed in patient samples. All samples showed a strong PCR amplification signal, indicating a high acetylated state for H4, validating our cell lines results.
SMRT level in MM cell lines and patients. The acetylation state of histones can be regulated by the recruitment of HDACs. HDACs (particularly HDAC3) are typically recruited to promoter regions through interaction with nuclear corepressors such as SMRT. Therefore, SMRT expression levels were assessed in MM and control cell lines. All MM cell lines studied presented a significantly reduced level of SMRT as compared with the EBV-LIN control cell line (Fig. 3A) . Quantitative analysis using real-time PCR confirmed a reduction in SMRT expression of f70% in the MM cell lines (Fig. 3B) . Finally, the SMRT protein expression level was assessed by immunofluorescence in both MM and control cell lines. A thorough scanning of the multiple spots (10 spots) showed that the control cell line EBV-LIN exhibited a normal level of SMRT protein, whereas little or no expression was observed in the MM cell lines (Fig. 3C) . These data indicate a loss of SMRT expression both at the mRNA and protein levels in JAG2-positive MM cell lines.
To validate the cell line results, three of the MM patient samples have been assessed for JAG2 as well as SMRT expression by RT-PCR. All three samples showed JAG2 overexpression and partial SMRT down-regulation (Fig. 3D) .
SMRT recruitment of HDAC3. Previously established SMRT recruits active HDAC3 by forming a complex that regulates acetylation-deacetylation in the core histones (22) . Because SMRT is partially down-regulated in MM, we aimed at determining the relative level of active HDAC3 recruited to the SMRT complex. Immunoprecipitation with a SMRT antibody was done on RPMI-8226, OPM2, and EBV-LIN cells followed by Western blot with an anti-HDAC3 mAb. Consistent with the SMRT expression results, the MM cell lines showed a reduced HDAC3 recruitment as compared with the control cells (Fig. 4) . These experiments suggest a direct correlation between constitutive acetylation (H4) of the core promoter in the MM cells and reduced levels of the SMRT corepressor that recruits HDAC3 to promoter regions.
Restoration of SMRT function by a SMRT-TAT recombinant protein. To further establish that SMRT regulates JAG2 expression, as suggested by our previous observations, a SMRT recombinant protein subcloned in frame with the TAT protein transduction domain from the HIV virus was purified.
To confirm the uptake of the recombinant protein by the MM cells, cells were incubated with SMRT-TAT fusion protein and GST-TAT scrambled protein, followed by a double color immunofluoroscence with anti-GST and anti-SMRT antibodies (Fig. 5A) . The results confirmed a successful and efficient transduction of the recombinant protein into the cell nuclei.
Treatment of the RPMI-8226 cells with the SMRT-TAT recombinant protein induced JAG2 down-regulation (Fig. 5B) , whereas no effect on JAG2 expression was observed when the TAT scrambled protein was used.
In addition, the effect of fusion protein on cell survival was assessed. Following 4 hours of incubation of RPMI-8226 with the SMRT-TATand scrambled protein, cells were washed and cultured in normal medium for 24 hours. A quantitative apoptosis assay (Annexin V) revealed a marked decrease (>45%) of the viability of the RPMI-8226 (MM) cells. Finally, different concentrations of the SMRT-TAT protein were tested. By MTT assay, all three doses (50, 100, and 150 ng) showed a significant effect on cell viability at 24 hours, whereas only the higher doses (100 and 150 ng) showed a similar effect at 48 hours. These data indicate that the SMRT function restoration is effective at 24 hours for all three doses; however, the effect is either lost or overcompensated by the proliferation rate with the lower dose used in the 48-hour experiments.
Discussion
We have previously established that the overexpression of NOTCH ligand JAG2 plays a crucial role in the development and propagation of malignant plasma cells in MM. Others have also reported on the role of the NOTCH pathway in MM (12) (13) (14) . JAG2 was also reported to be overexpressed in most MM cell lines studied by cDNA array (24) .
In this report, we investigated the underlying mechanism(s) for JAG2 overexpression in MM plasma cells. Gene expression can be regulated by promoter region epigenetic modifications such as DNA methylation and histone acetylation. We therefore investigated the potential alterations of the JAG2 promoter region. The promoter sequence of JAG2 has previously been characterized (25) , and the putative core promoter sequence as well as several binding sites has been identified in this region. CpG island methylation is a well-characterized epigenetic way in which gene transcription can be abnormally up-regulated or downregulated in nearly all types of cancer. Although CpG island hypermethylation is most commonly reported in cancer, some genes, such as the cancer-testis antigen genes, show hypomethylation at the CpG island contained in their promoters, which is associated with overexpression in cancer (26) . We previously reported a potential involvement of DNA methylation of the CpG island spanning the JAG2 promoter region (12) . To further validate this hypothesis, bisulfate-treated DNA sequencing in a series of MM cell lines and controls was done. The results showed no methylation in the core promoter regardless of JAG2 expression. Variable methylation was detected both upstream and downstream of the core promoter; however, no specific methylation pattern could distinguish JAG2-positive from JAG2-negative cells. The fact that the core promoter region is completely devoid of DNA methylation, even in nonexpressing cells, strongly argues against the hypothesis that JAG2 overexpression in MM cells is a consequence of the hypomethylation of the JAG2 promoter in MM cells.
This observation led us to investigate other epigenetic mechanisms of expression regulation. The chromatin structure, particularly the histone acetylation/deacetylation balance, plays an important role in gene expression regulation. Nucleosomal core histones like H2A H2B, H3, and H4 contain positively charged lysine-rich NH 2 termini, which bind tightly with negatively charged DNA (27) . The balance of acetylation-deacetylation of these lysine residues is usually achieved by two classes of enzymes: histone acetyltransferases and HDACs. Histone acetylation on lysine residues neutralizes the net charge on histones; as a result, DNA loosens its interaction with lysine, thus facilitating the transcription of the specific gene. These data have led us to verify the acetylation status of histones H3 and H4 in the JAG2 core promoter. Our results indicate a substantial difference of H4 acetylation level in the JAG2 core promoter in MM cell lines as well as in patient samples compared with control, although the H3 acetylation level seems to be similar in both cell types. This indicates that the overall acetylation (H4) level in core histones is higher in MM cells and therefore could contribute to the JAG2 overexpression observed. We could speculate that the decrease in H4 deacetylation might be due to blocking of function of specific HDAC, such as HDAC3.
The acetylation of histones can be regulated by the recruitment of HDACs. HDACs are typically recruited to promoter regions through interactions with nuclear corepressors such as SMRT. The SMRT/NcoR2 complex mediates transcriptional repression by forming complexes with msin3A/B and HDACs, in particular HDAC3, to induce local chromatin decondensation (28) . We therefore investigated the SMRT levels in MM cell lines as well as patient samples at both RNA and protein levels and observed a partial down-regulation of SMRT in both MM cells and patient samples. It has been reported that knocking down SMRT and NCoR led to the hyperacetylation of H3 and H4 in promoter regions (29) . Although we did not show any significant difference in the level of H3 acetylation, the H4 acetylation results obtained correlate with these observations.
The deacetylase activation domain of the SMRT protein interacts with HDAC3 to activate it (28, 30) . Because SMRT is partially down in MM cells and H4 acetylation level is high in the JAG2 core promoter, it is possible that regulated MM cells contain a lower amount of active HDAC3. Immunoprecipitation to pull down the SMRT-HDAC3 complex followed by a Western blot with an anti-HDAC3 antibody confirmed our hypothesis.
It should be noted that SMRT may not be the only corepressor. Other corepressors such as NCOR and mSin3A may compensate the SMRT down-regulation observed in MM cells. We therefore assessed the expression levels of both NCOR and mSin3A; however, no significant differences between MM and control cells have been observed (results not shown).
To further establish that SMRT regulates JAG2 expression, we developed a SMRT recombinant protein fused to HIV-TAT protein transduction domain (31) as a tool for SMRT function restoration. The fusion protein consisting of the protein transduction domain, TAT, and the protein of interest is added to the culture medium, and TAT along with the fused protein enters the cell by a receptorand energy-independent pathway (32) (33) (34) . It also contains the nuclear localization signal, which assists to overcome the nuclear membrane.
We assessed the effect of this transduced SMRT recombinant protein on the survival of MM cells by MTT assay. To confirm the mechanism of action of this recombinant protein, we also measured JAG2 expression both at the RNA and protein levels. Our observations of massive cell death on reintroduction of a functional SMRT protein into MM cells can be explained by partial restoration of SMRT repression activity, leading to the regulation of JAG2 overexpression. Unfortunately, we do not know the exact mechanism of this restoration; however, one of the possibilities is that the transduced SMRT recombinant protein might recruit more active HDAC3 to the promoter, which eventually regulates JAG2 expression. In addition, we also reported that down-regulation of SMRT can jeopardize several gene functions that play an important role in apoptosis (35) . Therefore, restoration of SMRT activity by this fusion protein might correct the overexpression of antiapoptotic genes, and as a result, a significant cell death was observed. Our group has also shown that restoration of SMRT function in non-Hodgkin lymphoma cell lines can induce apoptosis (35) , whereas normal cells do not seem to be affected by the SMRT-TAT fusion protein, probably due to the presence of normal endogenous SMRT protein level. Interestingly, the SMRT-TAT recombinant protein induces MM cells to die even though they are not in coculture. We have shown that MM cells themselves can express NOTCH ligands and receptors (12) ; therefore, interaction between MM cells themselves might be inhibited by restoration of SMRT activity by the recombinant protein.
The observations suggest a model where partial down-regulation of SMRT plays an important role in overexpression of JAG2 in MM. Down-regulated SMRT recruits a lower amount of active HDAC3 to JAG2 promoter. As a result, the deacetylation process of histones in the promoter region has been impaired and the cells have lost their transcriptional regulation of JAG2. This is the first report of SMRT alteration and its direct involvement in MM pathogenesis. In addition, the restoration of SMRT function certainly opens a new area of research for the development of new potential therapeutic approaches in MM.
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